266 related articles for article (PubMed ID: 27677836)
1. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry.
Dávila-Seijo P; Dauden E; Descalzo MA; Carretero G; Carrascosa JM; Vanaclocha F; Gómez-García FJ; De la Cueva-Dobao P; Herrera-Ceballos E; Belinchón I; López-Estebaranz JL; Alsina M; Sánchez-Carazo JL; Ferrán M; Torrado R; Ferrandiz C; Rivera R; Llamas M; Jiménez-Puya R; García-Doval I;
J Invest Dermatol; 2017 Feb; 137(2):313-321. PubMed ID: 27677836
[TBL] [Abstract][Full Text] [Related]
2. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
Carretero G; Ferrandiz C; Dauden E; Vanaclocha Sebastián F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina-Gibert M; López-Estebaranz JL; Ferrán M; Torrado R; Carrascosa JM; Carazo C; Rivera R; Jiménez-Puya R; García-Doval I;
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):156-63. PubMed ID: 24684267
[TBL] [Abstract][Full Text] [Related]
3. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
[TBL] [Abstract][Full Text] [Related]
4. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry.
Daudén E; Carretero G; Rivera R; Ferrándiz C; Llamas-Velasco M; de la Cueva P; Belinchón I; Gómez-García FJ; Herrera-Acosta E; Ruiz-Genao DP; Ferrán-Farrés M; Alsina M; Baniandrés-Rodríguez O; Sánchez-Carazo JL; Sahuquillo-Torralba A; Fernández-Freire LR; Vilar-Alejo J; García-Donoso C; Carrascosa JM; Herrera-Ceballos E; López-Estebaranz JL; Botella-Estrada R; Segovia-Muñoz E; Descalzo MA; García-Doval I;
J Am Acad Dermatol; 2020 Jul; 83(1):139-150. PubMed ID: 32213306
[TBL] [Abstract][Full Text] [Related]
6. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
[TBL] [Abstract][Full Text] [Related]
7. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
Busard CI; Cohen AD; Wolf P; Gkalpakiotis S; Cazzaniga S; Stern RS; Hutten BA; Feldhamer I; Quehenberger F; Lichem R; Kojanova M; Adenubiova E; Addis A; Naldi L; Spuls PI
J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):245-253. PubMed ID: 28898541
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort.
Ahlehoff O; Skov L; Gislason G; Gniadecki R; Iversen L; Bryld LE; Lasthein S; Lindhardsen J; Kristensen SL; Torp-Pedersen C; Hansen PR
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1128-34. PubMed ID: 25303139
[TBL] [Abstract][Full Text] [Related]
9. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
10. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.
Rungapiromnan W; Mason KJ; Lunt M; McElhone K; Burden AD; Rutter MK; Warren RB; Griffiths CEM; Ashcroft DM;
J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):769-778. PubMed ID: 31633837
[TBL] [Abstract][Full Text] [Related]
11. Biologics combined with conventional systemic agents for the treatment of children with severe psoriasis. Real-life data from the BiPe cohorts and a practice survey among French and Italian pediatric dermatologists.
Mahé E; Beauchet A; Hadj-Rabia S; Mazereeuw-Hautier J; Mallet S; Phan A; Severino-Freire M; Boralevi F; Aubert H; Barthélémy H; Girard C; Martin L; Piram M; Barbarot S; Balguerie X; Zitouni J; Phan C; Di Lernia V;
Dermatol Ther; 2022 Nov; 35(11):e15828. PubMed ID: 36107157
[TBL] [Abstract][Full Text] [Related]
12. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry.
Becker I; Horneff G
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):552-560. PubMed ID: 27390133
[TBL] [Abstract][Full Text] [Related]
13. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis.
Dávila-Seijo P; Dauden E; Carretero G; Ferrandiz C; Vanaclocha F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina M; López-Estebaranz JL; Ferrán M; Torrado R; Carrascosa JM; Llamas M; Rivera R; Jiménez-Puya R; García-Doval I;
J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):1942-1950. PubMed ID: 27329511
[TBL] [Abstract][Full Text] [Related]
14. Biologic drug survival in Israeli psoriasis patients.
Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials.
Papp KA; Armstrong AW; Reich K; Karunaratne M; Valdecantos W
Am J Clin Dermatol; 2016 Feb; 17(1):79-86. PubMed ID: 26547918
[TBL] [Abstract][Full Text] [Related]
16. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.
Heinecke GM; Luber AJ; Levitt JO; Lebwohl MG
J Drugs Dermatol; 2013 Oct; 12(10):1098-102. PubMed ID: 24085044
[TBL] [Abstract][Full Text] [Related]
17. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
18. Risk of Infection in Children With Psoriasis Receiving Treatment With Ustekinumab, Etanercept, or Methotrexate Before and After Labeling Expansion.
Schneeweiss MC; Savage TJ; Wyss R; Jin Y; Schoder K; Merola JF; Sidbury R; Oduol T; Schneeweiss S; Glynn RJ
JAMA Dermatol; 2023 Mar; 159(3):289-298. PubMed ID: 36753234
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of systemic treatments for psoriasis in elderly patients.
Piaserico S; Conti A; Lo Console F; De Simone C; Prestinari F; Mazzotta A; Gualdi G; Guarneri C; Borsari S; Cassano N
Acta Derm Venereol; 2014 May; 94(3):293-7. PubMed ID: 24158307
[TBL] [Abstract][Full Text] [Related]
20. Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis.
Dommasch ED; Kim SC; Lee MP; Gagne JJ
JAMA Dermatol; 2019 Oct; 155(10):1142-1152. PubMed ID: 31075163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
